Immuron Ltd — Capital/Financing Update 2010

Jun 10, 2010

==> picture [193 x 41] intentionally omitted <==

ASX Release

11 June 2010

Immuron Ltd ABN 80 063 114 045

Corporate Details:

Melbourne and Sydney 11[th] June, 2010:

Immuron and Nycomed intend to expand negotiations for the ‘Travelan’ product from Australia into other territories.

ASX Code: IMC

Directors

Chairman:

Prof Colin Chapman Non-Executive Directors: Prof. Roy Robins-Browne Mr Simon Sallka Dr Elane Zelcer

Chief Executive Officer

Following the successful license of Immuron’s ‘Travelan’™ product to Nycomed Australia Pty Ltd, the two companies have agreed to expand the current ‘Travelan’™ range in Australia and New Zealand through the development of other formulations which will target the indication of reducing the symptoms of minor gastro-intestinal disorders.

In addition, Nycomed Global have indicated that they wish to negotiate further license agreements for the distribution of Travelan™ to Brazil and Russia together with other selected countries in Europe and Asia.

Dr Grant Rawlin

Major Shareholder About Nycom Hadasit Medical Research 19.56%

ENDS

Contact Details:

Immuron Ltd Level 1 39 Leveson Street North Melbourne VIC 3051 Australia Tel: +61 (0)3 9018 4880 www.immuron.com

About Nycomed

Nycomed is a privately owned pharmaceutical company that provides medicines for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. Nycomed is one of the top 25 global pharmaceutical companies and 16[th] in rank world-wide for consumer healthcare products with a total net turnover of more than 3.5 billion Euro (AU$6 billion). Nycomed Australia, based in Sydney, has grown quickly over the last 7 years to achieve over AU$100 million turnover and employ 150 staff locally. Nycomed is most active in the areas of gastroenterology, respiratory diseases, pain management and tissue management. A key corporate strategy within Nycomed is to license in new promising products and to work with innovative partners to co-develop their concepts to a profitable conclusion.

About Immuron Limited, Immuron is a biopharmaceutical company focused on oral immunotherapy using dairyderived polyclonal antibody products for humans. Current products target infectious diseases of the gastrointestinal tract eg ‘ Travelan ’ targets travellers’ diarrhoea. More recent projects are targeting immunotherapy to influence chronic diseases such as diabetes type 2 and fatty liver (NASH), and to prevent and treat respiratory infection with influenza. Immuron’s main scientific alliances are with Hadassah Medical Centre (Israel) and University of Melbourne (Australia).

==> picture [162 x 107] intentionally omitted <==

Dr Grant Rawlin

Chief Executive Officer

For more information please contact:

Company Media Relations Grant Rawlin – CEO Fay Weston – Director Immuron Limited Talk Biotech Tel: 03 9018 4880 Tel: 02 4885 2662 or 0422 206036 E: grant@immuron.com E: fayweston@talkbiotech.com.au